Abstract
RON (Receptuer dOrigine Nantaise) is a member of the MET receptor tyrosine kinase family. RON is expressed in various cell types including macrophages, epithelial and hematopoietic cells. Its ligand, macrophage stimulating protein (MSP, also known as hepatocyte growth factor-like protein), is a multifunctional factor regulating cell growth and survival, adhesion and motility, cytokine production and phagocytosis. Accumulated data indicate that in addition to the regulation of normal cell functions, RON can be involved in cancer development and progression: (i) RON is overexpressed and constitutively active in some primary tumors and tumor cell lines, (ii) experimental mutations of RON cause oncogenic cell transformation, and (iii) RON mediates susceptibility to Friend-virus-induced erythroleukemia in mice. Constitutive activation of intracellular signaling pathways such as the PI-3 kinase / AKT, beta-catenin, MAPK and JNK pathways may underlie the molecular mechanism of RON-mediated oncogenic cell transformation. The present review describes RON-activated signaling pathways, which may play an important role in tumor formation and metastasis.
Keywords: oncogenic signaling, ron, met receptor, ron receptor tyrosine kinase
Current Cancer Drug Targets
Title: Oncogenic Signaling Pathways Activated by RON Receptor Tyrosine Kinase
Volume: 3 Issue: 1
Author(s): Alla Danilkovitch-Miagkova
Affiliation:
Keywords: oncogenic signaling, ron, met receptor, ron receptor tyrosine kinase
Abstract: RON (Receptuer dOrigine Nantaise) is a member of the MET receptor tyrosine kinase family. RON is expressed in various cell types including macrophages, epithelial and hematopoietic cells. Its ligand, macrophage stimulating protein (MSP, also known as hepatocyte growth factor-like protein), is a multifunctional factor regulating cell growth and survival, adhesion and motility, cytokine production and phagocytosis. Accumulated data indicate that in addition to the regulation of normal cell functions, RON can be involved in cancer development and progression: (i) RON is overexpressed and constitutively active in some primary tumors and tumor cell lines, (ii) experimental mutations of RON cause oncogenic cell transformation, and (iii) RON mediates susceptibility to Friend-virus-induced erythroleukemia in mice. Constitutive activation of intracellular signaling pathways such as the PI-3 kinase / AKT, beta-catenin, MAPK and JNK pathways may underlie the molecular mechanism of RON-mediated oncogenic cell transformation. The present review describes RON-activated signaling pathways, which may play an important role in tumor formation and metastasis.
Export Options
About this article
Cite this article as:
Danilkovitch-Miagkova Alla, Oncogenic Signaling Pathways Activated by RON Receptor Tyrosine Kinase, Current Cancer Drug Targets 2003; 3 (1) . https://dx.doi.org/10.2174/1568009033333745
DOI https://dx.doi.org/10.2174/1568009033333745 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Deaza Analogs of Folic Acid as Antitumor Agents
Current Pharmaceutical Design MicroRNA-34 Family, Mechanisms of Action in Cancer: A Review
Current Cancer Drug Targets Preface
Current Molecular Medicine Gonadotropin-Releasing Hormone Receptor Signaling: Biased and Unbiased
Mini-Reviews in Medicinal Chemistry Novel Functionalization for Maximizing Cell Turnover from Microcarrier
Current Biotechnology Nuclear Hormone Receptors and Female Reproduction
Current Molecular Medicine Impact of Curcumin on Microsomal Enzyme Activities: Drug Interaction and Chemopreventive Studies
Current Medicinal Chemistry Cellular Relationships of Testicular Germ Cell Tumors Determined by Partial Canonical Correlation Analysis of Gene Expression Signatures
Current Bioinformatics Pharmacologic Activation of p53 by Small-Molecule MDM2 Antagonists
Current Pharmaceutical Design Standardization of Epitopes for Human Chorionic Gonadotropin (hCG) Immunoassays
Current Medicinal Chemistry Dextran-based Nanocarriers for Delivery of Bioactives
Current Pharmaceutical Design Folate Receptor Targeted Liposomes
Drug Design Reviews - Online (Discontinued) DNA Drug Design for Cancer Therapy
Current Pharmaceutical Design Phytochemical-Mediated Glioma Targeted Treatment: Drug Resistance and Novel Delivery Systems
Current Medicinal Chemistry Genomic and Epigenetic Complexity of the FOXF1 Locus in 16q24.1: Implications for Development and Disease
Current Genomics Cell Proliferation and Cytotoxicity Assays
Current Pharmaceutical Biotechnology Cadmium and Its Epigenetic Effects
Current Medicinal Chemistry The Role of Trophoblast Nutrient and Ion Transporters in the Development of Pregnancy Complications and Adult Disease
Current Vascular Pharmacology Bioinformatics of Protein-Protein Interfaces and Small Molecule Effectors
Current Bioinformatics Recent Progress in Research on Ribosome Inactivating Proteins
Current Protein & Peptide Science